BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders
By Dr. Matthew Watson
LAS VEGAS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives Inc. (OTC: BDPT), a forward-thinking innovator in health and wellness solutions, is pleased to announce that FINRA has approved a dividend to its common stock shareholders. The decision to issue the dividend reflects the company’s gratitude for the unwavering support of its shareholders and their confidence in BioAdaptives’ mission and growth trajectory. Dividends were only paid to common stockholders, not to preferred stockholders.
Link:
BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders
Related Post
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
- Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
- Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
- Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
- Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
- Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
- Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
- RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
- Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
- Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
- Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
- Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd - January 22nd, 2025
- Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
- NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
- Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
- Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
- Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
- ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
- Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025
- Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - January 14th, 2025
- Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - January 14th, 2025
- Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - January 14th, 2025
- Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - January 14th, 2025
- ProMIS Neurosciences Issues Letter to Shareholders - January 14th, 2025
- BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - January 14th, 2025
- OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer - January 14th, 2025
- Correction: GUERBET : Financial agenda for 2025 - January 14th, 2025
- Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without... - January 14th, 2025
- Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - January 14th, 2025
- Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - January 14th, 2025
- FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s... - January 14th, 2025
- Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - January 14th, 2025
- HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - January 14th, 2025
- Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
- Idorsia publishes an invitation to a bondholder meeting - January 14th, 2025
- Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease - January 14th, 2025
- Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy... - January 14th, 2025
- Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 5th, 2025
- ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 5th, 2025
- SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - January 5th, 2025
- Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - January 5th, 2025
- Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - January 5th, 2025
- Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - January 5th, 2025
- Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc. - January 5th, 2025
- VALNEVA Declaration of shares and voting rights: December 31, 2024 - January 5th, 2025
- Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
- Procaps Group Receives Additional Delinquency Letter - January 5th, 2025
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 5th, 2025
- BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - January 5th, 2025
- Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week - January 5th, 2025
- Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5th, 2025
- BriaCell Announces Proposed Effective Date of Share Consolidation - January 5th, 2025
- PharmaTher Announces Grant of Stock Options - January 5th, 2025
- Oculis Publishes Notification of Major Changes in Voting Rights - January 5th, 2025
- Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 27th, 2024
- Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - December 27th, 2024
- Tevogen Bio to Host Panel "AI In Biopharma: Next Frontier of Medical Innovation" During the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD - December 27th, 2024
- Scientists report studies showing a novel drug repairs myelin and restores nervous system function in a model of multiple sclerosis - December 27th, 2024
- Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $24.0 Million - December 27th, 2024
- Abivax Announces a Change to the Composition of its Board of Directors - December 27th, 2024
- Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - December 27th, 2024
- Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference - December 27th, 2024
- Neuphoria Completes Re-domiciliation and Successor Listing on Nasdaq - December 27th, 2024
- Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca - December 27th, 2024
- Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc. - December 27th, 2024
- SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation - December 27th, 2024
- Optinose Announces 1-for-15 Reverse Stock Split - December 27th, 2024
- Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - December 27th, 2024
- Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing... - December 27th, 2024
- Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in... - December 27th, 2024
- Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - December 27th, 2024
- Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering - December 27th, 2024
- argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating... - December 27th, 2024
- T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally - December 18th, 2024
Global News Feed
Comments Off on BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders |
January 22nd, 2025
This author published 5992 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research